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Introduction
The survival rate of children and adolescents diagnosed 
with cancer has markedly improved in the last decades 
and now exceeds 85% in Switzerland [1]. This results in 
about 5700 childhood cancer survivors living in Switzer-
land, who have been diagnosed before age 14 years [2]. 
Most childhood cancer patients are cured from cancer and 
have decades of life ahead of them. Therefore, effective 
strategies to promote long-term health and quality of life 
are important. In this paper, we will briefly present ma-
jor late effects experienced by childhood cancer survivors, 
and describe ongoing initiatives in the field of childhood 
cancer survivorship and long-term follow-up care (LTFU) 
in Switzerland.
Late Effects
Medical late effects
Long-term complications and disabilities resulting from 
treatment toxicity or from the cancer itself can lead to 
chronic ill health and increased mortality years and de-
cades after cancer diagnosis [3, 4]. A large proportion of 
childhood cancer survivors experience late effects. At 45 
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years of age 95% have at least one chronic health condi-
tion and 80% have a severe, life-threatening, or disabling 
condition [5]. Frequently reported late effects are second 
primary cancers, cardiovascular diseases, endocrine dis-
orders, musculoskeletal problems, and secondary malig-
nancies [3]. In Switzerland, we found that survivors had a 
2-14 times higher risk to develop cardiovascular diseases 
[6], hearing loss [7], or pulmonary diseases [8] than their 
siblings. As the first generation of survivors’ age into their 
50s and 60s, it becomes evident that these chronic health 
conditions occur earlier than in peers and increase sub-
stantially over time.
Psychosocial late effects 
Late effects of childhood cancer are not limited to physical 
health, they include social and psychological problems, 
such as academic and employment difficulties, financial 
and insurance problems, psychological distress, and dif-
ficulties with family and intimate relationships [9]. Al-
though many survivors adapt well and experience positive 
psychological changes such as posttraumatic growth [10], 
around 1 in 4 is at risk for psychosocial sequelae [9, 11]. 
The risk for psychological distress and related psychoso-
cial needs is particularly high in women, those with a mi-
gration background, those with low household incomes, 
without siblings, who are older than 25 years of age, with 
cancer diagnosis between 5-14 years of age, and those with 
late effects [9, 12]. Most survivors report having at least 
one unmet psychosocial need [13], and different needs 
arise at different times of the cancer-survivorship trajec-
tory. Unmet needs include tailored age-specific personal-
ized information on late effects, lack of organized LTFU 
care, and support for psychological distress [14]. so
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Research initiatives in childhood cancer survivor-
ship: The current landscape in Switzerland
The Swiss Childhood Cancer Survivor Study (SCCSS) is 
a population-based, long-term cohort study [15] of all 
childhood cancer patients registered in the Swiss Child-
hood Cancer Registry (www.childhoodcancerregistry.ch) [16] 
since 1976. It monitors long-term outcomes and inves-
tigates factors associated with prognosis. It does not only 
assess survival on a national level, but also somatic health, 
chronic diseases, health behaviors, psychological and so-
cial wellbeing, and quality of life. Currently, it includes 
information on survival and second primary cancers from 
over 7600 survivors, and patient-reported outcomes data 
from over 3100 survivors and over 900 siblings [2]. The 
SCCSS analyses information from various sources: routine 
data on mortality and hospitalizations from the Swiss 
Federal Statistical office, incidence of secondary cancers 
from the cantonal cancer registries; patient-reported data 
from questionnaires; and detailed data on chemotherapy 
and radiotherapy, and on health outcomes from hospital 
charts. In addition to questionnaire-based research, the 
SCCSS recently has started to collect clinical data from 
standardized follow-up examinations in Swiss Pediatric 
Oncology clinics. This allows to identify late effects at an 
early stage, for instance by echocardiography, audiometry 
or lung function tests, and thus to optimize and individu-
alize follow-up care and secondary prevention. The SCCSS 
collaborates closely with survivors, their parents and phy-
sicians, so that results are immediately available to inform 
health care and supportive services. 
The Pediatric Oncology-Hematology clinic in Geneva 
(Prof. Marc Ansari) hosts the national Germline DNA 
Biobank Switzerland for Childhood Cancer and Blood 
Disorders (BISKIDS). There, germline DNA is collected 
on a national level from all childhood cancer patients and 
survivors. Analysis of gene-treatment interactions will en-
able researchers to develop more personalized therapy and 
care in the future. The Children’s Hospital Zurich (Prof. 
Jean-Pierre Bourquin) leads the National Swiss Pediatric 
Hematology/Oncology Biobanking Network (SPHO), a 
collection of liquid and solid tumour tissue samples. Both 
biobanks closely collaborate with the SCCSS. A national 
IT platform to link these three datasets is currently be-
ing developed in the framework of an SNF Biolink grant 
(The Swiss Pediatric Hematology/Oncology Metabank – 
a network for precision medicine research). This national 
platform will contain a comprehensive dataset for future 
patient-centred high-quality research. 
The University of Luzern has a focus on psychosocial as-
pects of childhood cancer and survivorship covering psy-
chosocial problems in survivors and the family. Their re-
search additionally addresses the organisation of LTFU, 
especially psychosocial LTFU.
Finally, researchers from the University of Bern and Lu-
zern collaborate in the International Guideline Harmoni-
zation Group (IGHG, http://www.ighg.org/), where they 
write systematic reviews and develop evidence-based, 
standardized guidelines for clinical follow-up to improve 
the health and quality of life of childhood cancer survivors 
in Switzerland and worldwide. 
Swiss services for childhood cancer survivors
The national organization Childhood Cancer Switzerland 
supports initiatives to improve follow-up care and col-
laborates closely with the international childhood cancer 
community. They recently established the Competence 
Center for Survivorship Issues, which offers a unique pos-
sibility for survivors and health care professionals to get 
support and information about LTFU and planned activi-
ties to meet, support, and exchange experiences. It orga-
nizes conferences, workshops and campaigns to raise the 
awareness of late effects and LTFU. Their active involve-
ment in the pediatric Swiss LTFU working group, consist-
ing of health care professionals, researchers, survivors, and 
parent representatives, reassures survivors input in LTFU 
initiatives. The LFTU working group aims to improve 
LTFU strategies through extensive exchange and collabo-
ration between the different stakeholders and the SPOG 
clinics. Recently, the working group endorsed the use of 
similar evidence-based late effect guidelines as a basis for 
the personalized LTFU recommendations in a position 
statement paper [17].
Long term follow-up 
With the growing population of childhood cancer survi-
vors, there is an increasing need to develop a range of sup-
port services of LTFU care in Switzerland that addresses 
medical and psychosocial issues. A systematic transition 
into adult care is necessary to avoid the risk of losing survi-
vors to LTFU. Currently, all Swiss pediatric oncology clin-
ics offer follow up care for at least 5-10 years [18]. How-
ever, only around 1 in every 4 survivors aged more than 
20 years attends LTFU after their discharge from Pediatric 
Oncology [19]. To improve the transition of LTFU in the 
adult care setting [17], it is important to establish multi-
disciplinary teams, which include adult specialists who 
work closely with pediatric oncologists and incorporate 
psychosocial support and vocational/academic counsel-
ling. Recently, more attention is being given to LTFU in 
Switzerland, which led to the first interdisciplinary LTFU 
clinics for adult childhood cancer survivors in Aarau, 
Bern, Geneva, and Liestal. More information about these 
LFTU clinics can be found on the website of Childhood 
Cancer Switzerland (https://www.kinderkrebs-schweiz.
ch). The majority of these LTFU clinics use comprehensive 
treatment summaries or survivor care plans at the time 
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of transition into adult care, with individualized LTFU 
recommendations based on earlier treatment. North-
American initiatives for personalized recommendations 
are implemented in Bern, Liestal (Passport for Care®), and 
Aarau (St. Jude’s survivorship care plan). These treatment 
summaries and care plans give survivors the necessary in-
formation to take responsibility of their own health. Fur-
thermore, the increased awareness through survivorship 
networks results in higher LTFU care demands, particu-
larly among older survivors who were previously lost to 
follow-up. This highlights the importance of harmoniz-
ing LTFU procedures within Switzerland and the need for 
reimbursement. There is also a need to raise awareness of 
interdisciplinary care of childhood cancer survivors among 
family doctors and specialists. 
In summary, the close collaboration between pediatric on-
cology and patient representatives has allowed to set up a 
large national network for comprehensive survivorship re-
search, which encompasses assessment of patient reported 
outcomes, monitoring of early late effects, establishment 
of germline DNA and tumor biobanks, and comprehen-
sive psychosocial and healthcare research on a national 
level. In the next years, priority should be given to raise 
awareness among health care professionals and survivors 
and to harmonize LTFU care services and survivorship 
care plans. 
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